<DOC>
	<DOCNO>NCT00387621</DOCNO>
	<brief_summary>In congestive heart failure , cardiac output low , blood pressure high , body becomes congest fluid . In normal people , high blood pressure , heart muscle cell secrete hormone excrete sodium water urine , reduce blood pressure . The action hormone call natriuretic response . The purpose study determine nesiritide improve impaired natriuretic response subject asymptomatic systolic heart failure asymptomatic diastolic heart failure .</brief_summary>
	<brief_title>Natriuretic Peptide System Therapy Human Preclinical Left Ventricle Dysfunction</brief_title>
	<detailed_description>The American Heart Association American College Cardiology define stage B heart failure ( HF ) asymptomatic subject abnormal heart structure/function . With advancement cardiac imaging biomarkers , abnormal heart structure function detect development symptom . Stage B HF represent either diastolic systolic dysfunction increase risk adverse cardiac event development symptomatic HF . The broad objective study define integrate cardiorenal response acute volume expansion ( VE ) humans presystolic dysfunction ( PSD ) , prediastolic dysfunction ( PDD ) , normal cardiac function . We hypothesize impaired cardiorenal endocrine response acute VE PSD PDD characterize lack appropriate activation urinary cGMP urinary sodium excretion . Further , hypothesize PSD , PDD , normal control subject would respond similarly exogenous administration B-type natriuretic peptide ( BNP ) . The natriuretic peptide ( NPs ) family structurally similar genetically distinct peptide vasodilating , natriuretic , renin inhibiting , lusitropic property . Acute peptide therapy brain natriuretic peptide ( BNP ) infusion recently approve FDA therapeutic strategy treatment acute human decompensated congestive HF . We determine effect acute subcutaneous BNP placebo administration integrate cardiorenal humoral response acute sodium load ( sodium chloride 0.9 % 0.25 ml/kg/min 1 hour ) three group subject : Group 1 normal control , Group 2 PSD , Group 3 PDD . Doppler echocardiography tonometry use measure cardiac vascular function sodium load . Renal function study assess sodium excretion , renal plasma flow , glomerular filtration rate baseline , , sodium load . Blood drawn humoral analysis include catecholamine , renin , aldosterone , angiotensin II , atrial natriuretic peptide ( ANP ) , BNP , cyclic guanosine monophosphate ( cGMP ) baseline , , sodium load .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>Inclusion criterion normal control group : ejection fraction great 50 % normal Doppler diastolic function clinical sign symptom history cardiovascular renal disease prior use cardiovascular medication . Inclusion criterion presystolic dysfunction group : ejection fraction le 40 % clinical sign symptom congestive heart failure ability perform 6minute walk &gt; 450 meter subject able walk 450 meter due pain hip knee fatigue shortness breath , still qualify study subject stable dos ACE inhibitor two week prior active study date previously prescribe cardiovascular medication allow , however , medication must stable dos two week prior study date . Inclusion criterion prediastolic dysfunction group : ejection fraction great 50 % moderate severe diastolic dysfunction assess Doppler echocardiography sign symptom congestive heart failure ability perform 6minute walk &gt; 450 meter subject able walk 450 meter due pain hip knee fatigue shortness breath , still qualify study previously prescribe cardiovascular medication allow , however , medication must stable dos two week prior study date . Exclusion criterion group : myocardial infarction within 3 month screen unstable angina within 14 day screen , evidence myocardial ischemia significant valvular stenosis , hypertrophic , restrictive obstructive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , biopsy proven active myocarditis severe congenital heart disease sustain ventricular tachycardia ventricular fibrillation within 14 day screen second third degree heart block without permanent cardiac pacemaker stroke within 3 month screen , evidence significantly compromise CNS perfusion total bilirubin &gt; 1.5 mg/dL liver enzymes &gt; 1.5 time upper limit normal serum creatinine &gt; 3.0 mg/dL serum sodium &lt; 125 mEq/dL &gt; 160 mEq/dL serum potassium &lt; 3.5 mEq/dL &gt; 5.0 mEq/dL serum digoxin level &gt; 2.0 ng/ml systolic pressure &lt; 85 mmHg hemoglobin &lt; 10 gm/dl acute chronic medical condition laboratory abnormality may increase risk associate study participation may interfere interpretation data receive investigational drug within 1 month prior dose patient allergy iodine opinion investigator , unlikely comply study protocol unsuitable reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>heart failure</keyword>
	<keyword>diastolic dysfunction</keyword>
	<keyword>systolic dysfunction</keyword>
	<keyword>preclinical</keyword>
	<keyword>natriuretic peptide</keyword>
	<keyword>B-type natriuretic peptide</keyword>
	<keyword>cyclic guanosine monophosphate</keyword>
</DOC>